Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs MasterCard Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while MasterCard Inc trades at $538.31 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 59.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and MasterCard Inc pays a 0.65% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MA | |
|---|---|---|
Market Cap | $8.04B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $598.96 |
52-Week Low | $241.71 | $471.55 |
Enterprise Value | $7.85B | $486.13B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Mastercard (MA) trades at $537.70, up 2.08% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79B in 2025, and net income margin remains robust at 45.88%. Analysts maintain a strong buy consensus, with a price target of $634.27, indicating ~18% upside. Recent news highlights institutional accumulation and AI-driven payment innovations.
The outlook for MA is positive, driven by earnings momentum and strategic expansion into digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With high profitability and institutional support, the stock presents a growth opportunity, though investors should monitor payment industry evolution and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
